RA Capital Management’s Adicet Bio ACET Stock Holding History

RA Capital Management’s Portfolio ACET Stock Details ACET Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$8.05M	Buy	1,182,624 +234,375	+25%	+$1.75M	0.09%	77
2025 Q4	$7.98M	Buy	948,249 +476,936	+101%	+$5.27M	0.08%	61
2025 Q3	$6.11M	Hold	471,313	–	–	0.08%	60
2025 Q2	$4.6M	Hold	471,313	–	–	0.08%	58
2025 Q1	$5.69M	Hold	471,313	–	–	0.1%	76
2024 Q4	$7.25M	Hold	471,313	–	–	0.1%	79
2024 Q3	$10.9M	Hold	471,313	–	–	0.13%	66
2024 Q2	$9.12M	Hold	471,313	–	–	0.12%	67
2024 Q1	$17.7M	Buy	+471,313	New	+$19.5M	0.23%	68
2022 Q4	–	Sell	-128,711	Closed	-$29.3M	–	71
2022 Q3	$29.3M	Buy	+128,711	New	+$32.7M	0.62%	47

Other funds holding ACET

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

SCM

Stonepine Capital Management Bend, Oregon $250M AUM 77.6% 1-Year Est. Return

Alyeska Investment Group Chicago, Illinois $35.4B AUM 33.54% 1-Year Est. Return

RA Capital Management's ACET Position: Q1 2026 in Review

RA Capital Management increased its Adicet Bio (ACET) stake by 25% in Q1 2026, buying an estimated $1.75M and bringing the position to 1,182,624 shares worth $8.05M. The position accounts for 0.09% of the portfolio, ranked #77.

RA Capital Management first reported a position in ACET in Q3 2022 and has held it in 10 quarters since. The position peaked at $29.3M in Q3 2022. 49 funds tracked by Wall St. Rank hold ACET as of Q1 2026.

RA Capital Management held 1,182,624 shares of Adicet Bio worth $8.05M as of Q1 2026.
RA Capital Management bought 234,375 Adicet Bio shares in Q1 2026, an estimated $1.75M.
Adicet Bio made up 0.09% of RA Capital Management's portfolio in Q1 2026, its #77 holding.
RA Capital Management first reported a position in Adicet Bio in Q3 2022 and has held it in 10 quarters since.
RA Capital Management's Adicet Bio position peaked at $29.3M in Q3 2022.
49 funds tracked by Wall St. Rank held Adicet Bio as of Q1 2026.

Based on RA Capital Management's 13F filing for Q1 2026, filed 15 May 2026.